(Q74063439)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

main subject

phase II clinical trial

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

G Heller

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

H I Scher

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

Contemporary Clinical Trials

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

360-368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900056-8

7 January 2021

Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900056-8

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900056-8

7 January 2021

Incorporating historical control data in planning phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900056-8

7 January 2021

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900056-8

7 January 2021

10.1016/S0197-2456(00)00056-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10913810%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference